GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » EPS (Diluted)

Ascentage Pharma Group International (HKSE:06855) EPS (Diluted) : HK$-1.39 (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International EPS (Diluted)?

Ascentage Pharma Group International's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-1.98. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.39.

Ascentage Pharma Group International's EPS (Basic) for the six months ended in Dec. 2023 was HK$-1.98. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.38.

Ascentage Pharma Group International's EPS without NRI for the six months ended in Dec. 2023 was HK$-1.98. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.39.

During the past 3 years, the average EPS without NRIGrowth Rate was 1.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Ascentage Pharma Group International's highest 3-Year average EPS without NRI Growth Rate was 35.00% per year. The lowest was -176.50% per year. And the median was -24.90% per year.


Ascentage Pharma Group International EPS (Diluted) Historical Data

The historical data trend for Ascentage Pharma Group International's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International EPS (Diluted) Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -14.12 -3.72 -3.76 -3.74 -3.59

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.81 -2.02 -1.61 -1.98 0.59

Competitive Comparison of Ascentage Pharma Group International's EPS (Diluted)

For the Biotechnology subindustry, Ascentage Pharma Group International's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's PE Ratio distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's PE Ratio falls into.



Ascentage Pharma Group International EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Ascentage Pharma Group International's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1012.442-0)/282.299
=-3.59

Ascentage Pharma Group International's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-572.359-0)/290.046
=-1.97

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascentage Pharma Group International  (HKSE:06855) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Ascentage Pharma Group International EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.
Executives
Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc 2301 Trustee
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Ascentage Pharma Group International Headlines

No Headlines